- Home
- BNR
as 12-23-2024 4:00pm EST
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.
| Founded: | 2014 | Country: | China |
| Employees: | N/A | City: | N/A |
| Market Cap: | 73.5M | IPO Year: | 2020 |
| Target Price: | N/A | AVG Volume (30 days): | 15.0K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.94 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.62 - $9.99 | Next Earning Date: | 12-31-2024 |
| Revenue: | $72,832,704 | Revenue Growth: | -8.54% |
| Revenue Growth (this year): | 52.9% | Revenue Growth (next year): | 48.35% |
Latest Burning Rock Biotech Limited News
BNR Breaking Stock News: Dive into BNR Ticker-Specific Updates for Smart Investing
TipRanks
19 days ago
Burning Rock Biotech’s Strategic Growth and Financial Results
GlobeNewswire
20 days ago
Burning Rock Reports Third Quarter 2024 Financial Results
GlobeNewswire
21 days ago
Burning Rock Announces 2024 Annual General Meeting to be Held on December 31, 2024
Simply Wall St.
a month ago
Burning Rock Biotech Leads The Charge With 2 Other US Penny Stocks
MT Newswires
2 months ago
Update: Burning Rock Biotech, Dizal's Lung Cancer Diagnostic Gets China Marketing Approval; Shares Jump Premarket
MT Newswires
2 months ago
Burning Rock Biotech, Dizal's Non-Small Cell Lung Cancer Treatment , Diagnostic Receives China Marketing Approval
GlobeNewswire
2 months ago
NMPA Grants Marketing Approval to the First Co-Developed NGS-Based Companion Diagnostic for Lung Cancer in China
GlobeNewswire
3 months ago
Burning Rock Announces Changes to Management and Board of Directors
Compare BNR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BNR Burning Rock Biotech Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.